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Evagelismos Hospital, Athens & Patras University 
Medical School, Patras, Greece  
 
 Renal artery sympathetic denervation, performed via a 
percutaneous catheter ablation procedure applying 
radiofrequency energy, has been developed to address 
renal sympathetic overactivity as a pivotal mechanism in 
the pathophysiology of hypertension.1 In 2009, the first-in-
man experience with this procedure was published.2 
Several studies followed, including the Symplicity HTN-1 
trial (n=45), the randomized Symplicity HTN-2 trial 
(n=106) and the expanded open-label Symplicity-2 study 
(n=153).3-6 However, all the initial evidence suffered from 
important limitations related to small cohort size, short 
follow-up and by and large incomplete data.1 According 
with a review and meta-analysis of 12 studies, most of 
them being observational studies without a control group, 
renal denervation in a total population of 561 patients with 
resistant hypertension, resulted in a significant reduction in 
mean blood pressure at 6 months.7 In the controlled studies 
(2 randomized controlled trials, n=133; and 1 
observational study with a control group, n=50), there was 
a reduction in mean systolic and diastolic blood pressure 
at 6 months of –28.9 mm Hg and –11.0 mm Hg, 
respectively, compared with the control groups (p < 
0.0001). In the uncontrolled studies (n=396), there was a 
reduction in mean systolic and diastolic blood pressure at 
6 months of –25.0 mm Hg and –10.0 mm Hg, respectively, 
compared with the pre-procedural values (p < 0.00001). 
One renal artery dissection and 4 femoral 
pseudoaneurysms were reported as procedural 
complications.7  
SYMPLICITY HTN-3 was a prospective, single-blind, 
randomized, sham-controlled trial8,9 of the effects of 
catheter-based renal denervation in 535 patients with 
severe resistant hypertension and systolic blood pressure 
>160 mmHg, who were receiving an antihypertensive 
regimen including at least 3 drugs, among which one was 
a diuretic. As detailed above, prior unblinded trials in 
similar cohorts indicated a favorable effect of this 
percutaneous procedure. Initially announced by Medtronic 
on January 9, 20148 and then presented in the 2014 
American College of Cardiology Meeting on March 29, 
2014, and simultaneously published in the New England 
Journal of Medicine,9 the results of this trial were negative 
for the primary efficacy end point which was the change in 
office systolic blood pressure at 6 months. The mean 
change in systolic blood pressure at 6 months was −14.13 
mm Hg in the denervation group and −11.74 mm Hg in the 
sham-procedure group, which is a nonsignificant 
difference of −2.39 mm Hg (P=0.26). Results were also 
negative for the secondary end-point, the change in mean 
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24-hour ambulatory systolic blood pressure (−6.75 in the 
denervation group and −4.79 mm Hg in the sham-
procedure group, a nonsignificant difference of −1.96 mm 
Hg; P=0.98). Finally, there were no significant differences 
in safety between the two groups: similar rates of death, 
end-stage renal disease, embolic events resulting in end-
organ damage, renovascular complications, or 
hypertensive crisis at 1 month or new renal-artery stenosis 
of >70% at 6 months.9  
 Since the announcement of these results, a heated 
debate has ensued whether this procedure is here to stay or 
doomed to oblivion.10-12 Those who consider these results 
as unblinding to the “truth”, talk about implausible results 
of prior studies (“too good to be true”), hopeful speculation 
and foggy hype, intervention bias, and time to close the 
book on renal denervation. Contrariwise, those who are 
still fan of the procedure claim otherwise, that the 
procedure is safe and here to stay, they point to technical 
inadequacies of the procedure being performed with a 
catheter providing single point focal ablation compared to 
other systems capable of circular ablation, perhaps the 
procedure was performed by less experienced operators; 
however, they admit that the page on renal denervation 
should be turned but the book should stay open, and there 
may be alternative methods to this procedure.  
 A common ground between these two views appears to 
converge towards the need for further well-controlled 
studies, with rigorous design similar to the design of 
Simplicity HTN-3 trial, perhaps with other technologies 
and newer generation devices and in more selective patient 
groups. Better guidance to the performance of the 
procedure should also be sought, as currently this 
procedure remains a blind procedure without a specific 
procedural end-point. The result is only seen clinically 
during follow-up.  
 Thus, whether negative or not-positive or neutral, and 
despite a plethora of speculations why so, the results of 
SIMPLICITY-HTN-3 trial raised serious questions about 
the efficacy of renal denervation in resistant hypertension 
and have significantly curtailed the initial enthusiasm 
about this procedure and its impact on the treatment of 
hypertension. Further subanalyses of this trial’s data may 
provide some insight and generate hypotheses whether 
there may exist any subgroups of patients who might 
benefit from the application of this procedure. Future 
clinical trials with newer generation ablation systems in 
more specific and select patient groups might shed further 
light on the fate of this procedure.  
 Perhaps, until more data become available, the Swiss 
Expert Consensus13 might be a pertinent guide for the use 
of this procedure: ● confirmation of truly resistant 
hypertension, ● exclusion of secondary forms of 
hypertension, ● a multidisciplinary decision confirming 
the eligibility, ● facilities that guarantee procedural safety 
and ● a long-term follow-up of the patients, if possible in 
cooperation with a hypertension specialist. The authors of 
this consensus indicate that these steps are essential until 
long-term data on safety and efficacy are available. All 
these, of course, should be explained to the patient and 
his/her family, together with the recent results of the 
SIMPLICITY HTN-3 trial, within the context of 
participatory medicine before obtaining a written informed 
consent for the procedure. Indeed, according with the 
Copenhagen experience, 10% of those referred for renal 
denervation had secondary forms of hypertension and 
together with other exclusions uncovered, only 51% were 
finally eligible for the procedure.14  
 Thus, until more data become available from further 
subanalyses of the SIMPLICITY HTN-3 trial or other 
appropriate trials, patients undergoing this procedure 
should be rigorously scrutinized and carefully selected, 
and perhaps better enrolled in investigation protocols. 
However, encouraging are the results of safety of the 
procedure from both the SIMPLICITY HTN-3 trial and the 
3-year report of the SIMPLICITY HTN-1 trial.8,15 Finally, 
some other novel areas of potential benefit of renal 
denervation might still be worth exploring, such as in 
patients with atrial fibrillation and patients with heart 
failure.16,17  
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Abstract 
Transvenous temporary cardiac pacing is a rather old 
but still contemporary life-saving technique, with a unique 
value in the treatment of critically ill patients suffering 
from rhythm disturbances and associated hemodynamic 
compromise. Physicians involved in the management of 
such patients should always keep in mind the indications 
and contraindications of transvenous temporary cardiac 
pacing, and should be at least familiar with the insertion 
technique and the post-insertion care.  
 
Key Words: temporary cardiac pacing; bradycardia; 
overdrive pacing 
 
List of Abbreviations 
 
AMI = acute myocardial infarction; AV = atrio-ventricular; BBB 
= bundle branch block; CHB = complete heart block; ECG = 
electrocardiogram; LAFB = left anterior fascicular block; LBBB 
= left bundle branch block; LPFB = left posterior fascicular 
block; RA = right atrium; RBBB = right branch bundle block; 
RV = right ventricle; SVT = supraventricular tachycardia; SuVT 
= sustained ventricular tachycardia; TCP = temporary cardiac 
pacing; TdP = torsade de pointes 
 
Introduction 
 
Temporary cardiac pacing is a life-saving procedure 
used as a means of electrical stimulation of the heart 
through the use of pacing leads, in order to treat 
dysrhythmias, until they are resolved or until a long-term 
therapy is adopted.1-5 Temporary pacing is effected via 
transvenous, transcutaneous, or epicardial approaches. 
Transcutaneous pacing is delivered via cutaneous adhesive 
pads placed in an anteroposterior position, has the 
advantage of being immediately available for emergency 
cases of asystole but it requires high energy to capture the 
heart, causing significant discomfort to the wake patient, 
and is reserved for those who are comatose or as a bridge 
until transvenous endocardial pacing is rendered 
feasible.1,5,6 Epicardial wires are routinely placed during 
cardiac surgery to provide backup pacing in the event of 
perioperative bradyarrhythmias, but also to diagnose and 
overdrive certain tachyarrhythmias (e.g. atrial flutter).7 
However, the most common and reliable approach to 
temporary pacing is provided with transvenous insertion of 
temporary pacing wire.1-5  
Transvenous temporary cardiac pacing (TCP) was first 
described by Furman et al in 1958 in dogs and in 1959 in 
human beings,8,9 initially for the correction of complete 
heart block, but the indications have subsequently 
expanded to comprise a variety of bradyarrhythmias but 
also a list of tachyarrhythmias, including the diagnosis and 
overdrive suppression of supraventricular and ventricular 
tachycardias.1,3,4 In its most common use of supporting the 
patient with bradycardia, temporary pacing typically 
serves as a bridge to a more definitive solution to a low 
heart rate, such as permanent pacemaker implantation, or 
resolution of a transient or reversible cause, e.g. 
bradycardic effect of drugs, electrolyte disturbance, 
inferior-wall myocardial infarction, etc.  
 
Indications  
 Transvenous temporary cardiac pacing is most 
commonly used to treat symptomatic bradycardia due to 
sinus node dysfunction or atrioventricular (AV) block. In 
